Amy Wesa

Amy Wesa is an accomplished professional in the field of precision medicine and biomarkers, currently serving as the Vice President at IO Biotech since January 2024. With extensive experience as a consultant since December 2017, Wesa has held significant leadership roles, including Senior Vice President of Preclinical and Translational Research at Vita Therapeutics and Vice President of Research and Development at Champions Oncology, where responsibilities encompassed overseeing immuno-oncology and hematologic malignancy portfolios. Previous roles include Associate Director at Intrexon Corporation, where Wesa developed CAR T cell research programs, and Director of Research & Development at Celsense, Inc. An academic background includes tenure as an Assistant Professor at the University of Pittsburgh School of Medicine, where Wesa focused on human cancer immunology and authored numerous publications. Wesa holds a Bachelor of Science in Biology from the University of Michigan, a PhD in Cancer Biology from Wayne State University School of Medicine, and completed postdoctoral studies in tumor immunology at the University of Pittsburgh.